全文获取类型
收费全文 | 2052篇 |
免费 | 109篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 137篇 |
妇产科学 | 70篇 |
基础医学 | 222篇 |
口腔科学 | 35篇 |
临床医学 | 174篇 |
内科学 | 329篇 |
皮肤病学 | 107篇 |
神经病学 | 260篇 |
特种医学 | 36篇 |
外科学 | 150篇 |
综合类 | 56篇 |
一般理论 | 6篇 |
预防医学 | 128篇 |
眼科学 | 60篇 |
药学 | 177篇 |
1篇 | |
中国医学 | 4篇 |
肿瘤学 | 211篇 |
出版年
2023年 | 20篇 |
2022年 | 42篇 |
2021年 | 88篇 |
2020年 | 62篇 |
2019年 | 57篇 |
2018年 | 66篇 |
2017年 | 54篇 |
2016年 | 76篇 |
2015年 | 66篇 |
2014年 | 85篇 |
2013年 | 113篇 |
2012年 | 214篇 |
2011年 | 213篇 |
2010年 | 84篇 |
2009年 | 82篇 |
2008年 | 126篇 |
2007年 | 135篇 |
2006年 | 114篇 |
2005年 | 116篇 |
2004年 | 95篇 |
2003年 | 77篇 |
2002年 | 64篇 |
2001年 | 7篇 |
2000年 | 5篇 |
1999年 | 6篇 |
1998年 | 12篇 |
1997年 | 16篇 |
1996年 | 7篇 |
1995年 | 8篇 |
1994年 | 4篇 |
1993年 | 7篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 4篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1974年 | 1篇 |
1973年 | 3篇 |
1971年 | 3篇 |
1970年 | 5篇 |
1969年 | 3篇 |
1968年 | 2篇 |
1967年 | 2篇 |
排序方式: 共有2168条查询结果,搜索用时 343 毫秒
41.
42.
Rashmi Chandra Yu Wang Rafiq A. Shahid Steven R. Vigna Neil J. Freedman Rodger A. Liddle 《The Journal of clinical investigation》2013,123(8):3343-3352
Cholecystokinin (CCK) is a satiety hormone produced by discrete enteroendocrine cells scattered among absorptive cells of the small intestine. CCK is released into blood following a meal; however, the mechanisms inducing hormone secretion are largely unknown. Ingested fat is the major stimulant of CCK secretion. We recently identified a novel member of the lipoprotein remnant receptor family known as immunoglobulin-like domain containing receptor 1 (ILDR1) in intestinal CCK cells and postulated that this receptor conveyed the signal for fat-stimulated CCK secretion. In the intestine, ILDR1 is expressed exclusively in CCK cells. Orogastric administration of fatty acids elevated blood levels of CCK in wild-type mice but not Ildr1-deficient mice, although the CCK secretory response to trypsin inhibitor was retained. The uptake of fluorescently labeled lipoproteins in ILDR1-transfected CHO cells and release of CCK from isolated intestinal cells required a unique combination of fatty acid plus HDL. CCK secretion secondary to ILDR1 activation was associated with increased [Ca2+]i, consistent with regulated hormone release. These findings demonstrate that ILDR1 regulates CCK release through a mechanism dependent on fatty acids and lipoproteins and that absorbed fatty acids regulate gastrointestinal hormone secretion. 相似文献
43.
44.
45.
46.
47.
The effects of neurotensin, a tridecapeptide localized mainly in the gut, on pancreatic secretion are controversial. It is not clear whether the effects are mediated by direct or indirect effects. The present study was done to determine the effect of threshold doses of neurotensinin vivo in the rat as well asin vitro to clarify whether the action is direct or indirect. Forin vivo studies the pancreatic duct of rats was cannulated and threshold doses of neurotensin and CCK-8 alone or in combination were infused as an intravenous bolus and pancreatic juice collected at 10-min intervals for 1 hr. Forin vitro studies dissociated lobules and acini were incubated for 1 hr with 10–11–10–6 M neurotensin with or without 10–9 M CCK-8 (maximally effective dose). Amylase secretion in the pancreatic juice or in the medium was determined. Neurotensin and CCK-8 at a dose of 50 pM/kg increased pancreatic protein secretionin vivo. Neurotensin in combination with CCK-8 did not potentiate protein secretion. In the pancreatic lobules and acini, neurotensin 10–11–10–6 M alone or in combination with CCK-8 (10–9 M) did not stimulate amylase secretion above the basal level or that stimulated with CCK-8. The combined data indicate that the effect of neurotensin is not mediated by a direct action on the pancreatic acinar cells.This work was supported by the Medical Research Service of the Veterans Administration. 相似文献
48.
Upendra Kaul Ripen K Gupta Kottaram K Haridas Saligrama S Ramesh Kamal K Sethi Balbir Singh Rajiv Agarwal Ram D Yadave Tapan Ghose Rakesh R Sapra Rajiv Bajaj Madhukar Shahi Ajit Bhagwat Pramod Kumar Omen P Mathews Pratik K Soni 《Catheterization and cardiovascular interventions》2002,57(4):497-503
The results of primary coronary stenting for acute myocardial infarction (AMI) have been reported to improve significantly with the concomitant administration of platelet glycoprotein IIb/IIIa inhibitor abciximab. There are, however, no data available with the use of eptifibatide, a more cost-effective, small-molecule GP IIb/IIIa blocker with a shorter half-life. In a prospective multicenter feasibility and efficacy study, we assigned 55 consecutive patients with AMI being taken up for primary stenting to receive eptifibatide just before the procedure (two boluses of 180 microg/kg 10 min apart and a 24-hr infusion of 2 microg/kg/min). Clinical outcomes were evaluated at 30 days after the procedure. The angiographic patency of the vessel with TIMI flow rates, TIMI myocardial perfusion (TMP) grade, and corrected TIMI frame counts were assessed at the end of procedure and before hospital discharge. At 30 days, the primary endpoint, a composite of death, myocardial infarction, and urgent target vessel revascularization (TVR) was seen in 12.7% of patients. The TIMI 3 and TMP grade 3 flow, which was seen in 93% and 86% of patient, respectively, at the end of the procedure, declined to 86% and 78%, respectively (P < 0.05) before hospital discharge. Corrected TIMI frame counts also decreased from 25.7 +/- 7.2 to 22.9 +/- 6.8 (P < 0.05). There were five (9.1%) instances of subacute thrombosis (SAT) presenting as AMI, needing urgent TVR in all, within 3-5 days of the primary procedure. No excessive bleeding complication, directly attributable to the use of eptifibatide, was observed. The study was terminated prematurely because of an unacceptable SAT rate. Administration of eptifibatide along with primary stenting for AMI is associated with a high TIMI 3 and TMP grade 3 flow acutely. However, these flows decline significantly before hospital discharge and lead to a high rate of SAT. The dosage and duration of infusion of eptifibatide in this setting needs further evaluation. 相似文献
49.
Roongta Rashmi Mondal Sumantro Haldar Subhankar Kumar Mavidi Sunil Ghosh Alakendu 《Clinical rheumatology》2022,41(5):1591-1596
Clinical Rheumatology - We report the case of an 18-year-old male with Still’s disease for the last 3 years, in remission, who developed two flares of his disease after receiving two... 相似文献
50.
Parihar Rashmi Shukla Ruchi Baishya Bikash Kalita Jayantee Haldar Rudrashish Misra Usha Kant 《Metabolic brain disease》2022,37(3):773-785
Metabolic Brain Disease - We report the potential role of 1H Nuclear Magnetic Resonance (NMR) based metabolomics in tuberculous meningitis (TBM). We also correlate the significant metabolites with... 相似文献